Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 13/20 | 0.57 |
| ▸ | CTSK | P43235 | 11/20 | 0.57 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.43 |
| ▸ | CTSG | P08311 | 1/20 | 0.43 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.43 |
| ▸ | CMA1 | P23946 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23200865 | 0.89 | CTSS (0.54) | CTSSCTSKCTSLCTSBPRSS1 | |
| SCHEMBL14448525 | 0.88 | CTSS (0.53) | CTSSCTSKCTSLCTSBPRSS1 | |
| SCHEMBL7114124 | 0.84 | CTSS (0.56) | CTSSCTSKCTSLCTSBTRPA1 | |
| SCHEMBL31724504 | 0.84 | CTSS (0.56) | CTSSCTSKCTSLCTSBTRPA1 | |
| SCHEMBL7045324 | 0.83 | CTSS (0.61) | CTSSCTSKCTSLCTSBPRSS1 | |
| Water SCHEMBL11877240 | 0.83 | CTSS (0.53) | CTSSCTSKCTSLCTSB | |
| SCHEMBL13149842 | 0.83 | ACACB (0.49) | CTSSCTSKCTSLCTSBPRSS1 | |
| SCHEMBL8172182 | 0.83 | ACACB (0.49) | CTSSCTSKCTSLCTSBPRSS1 | |
| SCHEMBL23224313 | 0.83 | ACACB (0.49) | CTSSCTSKCTSLCTSBPRSS1 | |
| SCHEMBL19490451 | 0.83 | CTSS (0.47) | CTSSCTSKCTSLCTSBPRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2185503-A1 | MONOAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2010-05-19 | — | — | EP | disclosed |
| WO-2009016087-A1 | MONOAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | WO | disclosed |
| US-20090036422-A1 | MONOAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036422-A1 | MONOAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, MTNR1A | CTSS 4504/4885CTSK 4783/4885CTSL 3769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.